CINECA IRIS Institutional Research Information System

CALCAGNO, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.435
EU - Europa 9.645
AS - Asia 4.944
SA - Sud America 458
AF - Africa 369
OC - Oceania 123
Continente sconosciuto - Info sul continente non disponibili 24
Totale 32.998
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.076
IT - Italia 2.192
CN - Cina 2.020
DK - Danimarca 1.386
SG - Singapore 1.155
IE - Irlanda 1.000
FR - Francia 745
SE - Svezia 745
DE - Germania 700
GB - Regno Unito 540
FI - Finlandia 466
UA - Ucraina 326
AT - Austria 305
ID - Indonesia 276
KR - Corea 273
VN - Vietnam 263
IN - India 252
ES - Italia 232
CA - Canada 231
PL - Polonia 228
BR - Brasile 223
NL - Olanda 204
JP - Giappone 171
ZA - Sudafrica 132
AU - Australia 112
MX - Messico 101
RO - Romania 100
RU - Federazione Russa 90
BE - Belgio 89
TW - Taiwan 86
HK - Hong Kong 83
TH - Thailandia 82
CH - Svizzera 76
TR - Turchia 65
AR - Argentina 59
CL - Cile 53
PE - Perù 51
CO - Colombia 49
PK - Pakistan 49
CZ - Repubblica Ceca 45
IR - Iran 40
PT - Portogallo 34
GR - Grecia 32
UG - Uganda 30
PH - Filippine 28
NG - Nigeria 25
EU - Europa 21
IL - Israele 20
EG - Egitto 18
ET - Etiopia 18
KE - Kenya 18
HU - Ungheria 17
TZ - Tanzania 16
NO - Norvegia 14
MY - Malesia 13
BG - Bulgaria 12
EC - Ecuador 12
HR - Croazia 12
NZ - Nuova Zelanda 11
SA - Arabia Saudita 11
SK - Slovacchia (Repubblica Slovacca) 11
SN - Senegal 11
MW - Malawi 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
ML - Mali 9
SD - Sudan 9
TN - Tunisia 8
UZ - Uzbekistan 8
GM - Gambi 7
LT - Lituania 7
MU - Mauritius 7
GH - Ghana 6
BY - Bielorussia 5
JO - Giordania 5
LU - Lussemburgo 5
LV - Lettonia 5
RS - Serbia 5
BO - Bolivia 4
CR - Costa Rica 4
CU - Cuba 4
EE - Estonia 4
GA - Gabon 4
GE - Georgia 4
HN - Honduras 4
KZ - Kazakistan 4
MD - Moldavia 4
MZ - Mozambico 4
NA - Namibia 4
PA - Panama 4
BH - Bahrain 3
CD - Congo 3
CM - Camerun 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
MA - Marocco 3
MO - Macao, regione amministrativa speciale della Cina 3
PR - Porto Rico 3
VE - Venezuela 3
ZW - Zimbabwe 3
Totale 32.947
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.899
Chandler 1.715
Beijing 1.074
Dublin 990
Fairfield 971
Singapore 940
Santa Clara 856
Ashburn 686
Houston 659
Wilmington 560
Torino 539
Woodbridge 475
Redwood City 394
Villeurbanne 394
Seattle 383
Dearborn 344
Medford 343
Princeton 311
Nyköping 307
Cambridge 299
Jacksonville 294
Columbus 290
Vienna 246
Pisa 227
Turin 217
Warsaw 210
Fremont 186
Jakarta 179
Milan 155
Dong Ket 125
New York 119
Boston 101
Guangzhou 97
San Diego 91
Shanghai 90
Helsinki 84
Hangzhou 67
Nanjing 66
Paris 66
Toronto 65
Boardman 62
Brussels 62
Washington 55
Taipei 53
Rome 51
Munich 48
Ottawa 47
São Paulo 45
Lima 44
Los Angeles 44
Phoenix 43
Cape Town 42
Hebei 42
London 41
Chicago 40
Kunming 40
Santiago 40
Seoul 39
Verona 39
Norwalk 37
Hong Kong 36
Barcelona 34
Hefei 33
Chengdu 32
Frankfurt am Main 30
Brno 29
Buenos Aires 29
Silver Spring 29
Tokyo 28
Hanoi 27
Omaha 27
Montreal 26
Amsterdam 25
Bengaluru 25
Falls Church 25
Madrid 25
Upper Marlboro 25
Buffalo 22
Central District 22
Melbourne 22
Arlington 21
Dallas 21
Wuhan 21
Jinan 20
Zhengzhou 20
Changsha 19
Duncan 19
Mumbai 19
Pune 19
Copenhagen 18
Montréal 18
Mountain View 18
San Francisco 18
Tariceni 18
Toulouse 18
Bangkok 17
Brescia 17
Nanchang 17
Nuremberg 17
Sydney 17
Totale 19.951
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 814
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 719
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 611
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 509
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 439
TB and COVID-19 co-infection: Rationale and aims of a global study 432
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 421
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 392
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 383
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 356
Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. 341
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 329
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 319
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 314
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 314
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 301
Heart failure in patients with human immunodeficiency virus: a review of the literature. 300
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 289
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 286
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 284
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 266
Raltegravir penetration in seminal plasma of healthy volunteers. 257
Health-care Associated KPC-BSI: The Time Has Come. 244
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 244
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 243
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 239
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 233
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 231
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 226
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 211
Prevalence and predictors of blood-brain barrier damage in the HAART era. 210
Acute HIV infection: Improved algorithms for HIV testing. 205
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 202
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 195
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 194
Anti-CD20 antibody therapy for B-cell lymphomas 191
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 183
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 182
Cardiovascular disease in HIV patients: from bench to bedside and backwards 182
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 181
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 181
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 178
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study 178
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 178
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 177
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 177
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 176
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 173
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 172
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 171
A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection 170
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 170
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 167
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 165
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia 165
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 165
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 163
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 163
Tuberculosis and COVID-19 co-infection: description of the global cohort 163
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 162
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 160
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 160
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 157
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 156
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 156
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 156
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 155
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 155
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 155
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 154
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 153
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 152
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 152
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 150
What do we know about tailoring treatment with tenofovir? 150
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 150
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 149
Louseborne relapsing fever among East African refugees, Italy, 2015 149
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 149
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 149
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 147
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 147
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 145
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 145
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 145
Antiretroviral Drug Penetration into the CNS Compartment 145
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 145
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 145
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 144
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 143
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series 143
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 142
Is Maraviroc a substrate for SLCO1B1? 136
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 136
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs 136
Is peritoneal fluid a sanctuary site for HIV? 134
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 134
Etravirine Plasma Exposure is Associated with virological Response in Experienced HIV-positive Patients 133
Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy 131
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. 128
Totale 21.757
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.791
article - articoli 0
book - libri 0
conference - conferenze 15.921
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.712
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.632 0 0 0 0 0 859 483 357 344 461 512 616
2020/20213.619 459 197 189 210 295 314 246 153 312 291 272 681
2021/20226.028 481 414 510 578 448 451 543 496 376 276 746 709
2022/20235.490 525 409 153 509 515 1.333 375 390 591 147 302 241
2023/20242.797 337 423 181 153 229 385 103 173 59 160 253 341
2024/20253.376 171 385 345 594 1.460 421 0 0 0 0 0 0
Totale 34.416